Quoin initiates clinical testing of QRX003 in pediatric NS trial

Quoin Pharmaceuticals (QNRX) announced that it has initiated the testing of the safety and efficacy of QRX003 in a young child with Netherton Syndrome, NS, a rare inherited genetic disease. There is currently no approved treatment for NS and no cure. “We are pleased to announce this latest initiative for Quoin as we strive to generate the broadest and most diverse data set possible for QRX003 in Netherton Syndrome patients. Furthermore, we are delighted that Professor Irvine, one of the world’s leading researchers in this disease, has agreed to perform this assessment of QRX003. Currently, we are testing patients aged 14 years and up in our two ongoing clinical studies and we hope that data generated by Professor Irvine will facilitate lowering the eligibility age further. In addition, we look forward to broadening the scope of this clinical assessment to include three additional pediatric subjects in Spain,” said Dr. Michael Myers, Quoin CEO.